Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
Volume 1851, Issue 1, Pages 40-50Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbalip.2014.09.021
Keywords
Dihydroceramide; Lipotoxicity; DEGS1; Desaturase
Funding
- Medical Research Council Programme [FP7-ETHERPATHS (KBBE-2007-2A-222639-2)]
- British Heart Foundation (BHF) [PG/08/003/24286]
- MRC [G0600717, MC_UU_12012/5, MC_UU_12012/2, G0802051] Funding Source: UKRI
- British Heart Foundation [RG/12/13/29853] Funding Source: researchfish
- Medical Research Council [G0802051, G0600717, MC_UU_12012/5, MC_UU_12012/2, MC_UU_12012/5/B, G0600717B] Funding Source: researchfish
Ask authors/readers for more resources
The pathogenic relevance of sphingolipid metabolism is increasingly being recognised. Here we elaborate on a new player within the sphingolipid field: the degs1 enzyme, a recently discovered enzyme that catalyses the final step in the de novo biosynthesis of ceramides controlling the step from dihydroceramides to ceramides. Here, we describe its function and dysregulation by factors such as oxidative stress, hypoxia and inflammation and provide evidence indicating that dihydroceramides constitute a biologically active molecule from the sphingolipid family with certain differential characteristics with respect to its delta-4 unsaturated counterparts, the ceramides. Finally we present pathophysiological scenarios characterised by specific increases in dihydroceramide that challenge the concept that all ceramides species are the same. This article is part of a Special Issue entitled Linking transcription to physiology in lipodomics. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available